Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Rocci, A."'
Autor:
Glavey SV; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Hematology, National University of Ireland, Galway, Ireland., Naba A; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Manier S; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Clauser K; Protemics Platform, Broad Institute, Cambridge, MA, USA., Tahri S; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Park J; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Reagan MR; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Moschetta M; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Mishima Y; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gambella M; University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Rocci A; Manchester Royal Infirmary and Central Manchester University Hospital NHS Foundation, University of Manchester, Manchester, UK., Sacco A; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; SST Spedali Civili, Department Medical Oncology, CREA Laboratory, Brescia, Italy., O'Dwyer ME; Department of Hematology, National University of Ireland, Galway, Ireland., Asara JM; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Palumbo A; University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Roccaro AM; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; SST Spedali Civili, Department Medical Oncology, CREA Laboratory, Brescia, Italy., Hynes RO; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Ghobrial IM; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Leukemia [Leukemia] 2017 Nov; Vol. 31 (11), pp. 2426-2434. Date of Electronic Publication: 2017 Mar 27.
Autor:
Amrita Krishnan, Marta Chesi, Enrico Caserta, Estelle Troadec, Domenico Viola, Emine Gulsen Gunes, Guido Marcucci, Abhay R. Satoskar, Alex E. Pozhitkov, Jayeeta Ghose, Alberto Rocci, Jihane Khalife, Cesar Terrazas, Steven D. Rosen, James F. Sanchez, Ada Dona, Marianna Martella, P. Leif Bergsagel, Craig C. Hofmeister, Jonathan J. Keats, Flavia Pichiorri
High levels of circulating miR-16 in the serum of multiple myeloma (MM) patients are independently associated with longer survival. Although the tumor suppressor function of intracellular miR-16 in MM plasma cells (PCs) has been elucidated, its extra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::623780f247348c0b1e29455d8132e5c5
https://europepmc.org/articles/PMC6948777/
https://europepmc.org/articles/PMC6948777/
Autor:
Aldo M. Roccaro, Siobhan Glavey, Antonio Sacco, John M. Asara, Michele Moschetta, Richard O. Hynes, Jihye Park, Karl R. Clauser, Antonio Palumbo, Yuji Mishima, Michael O'Dwyer, Alexandra Naba, Irene M. Ghobrial, Sabrin Tahri, Salomon Manier, Alberto Rocci, M. Gambella, Michaela R. Reagan
Publikováno v:
Leukemia. 31:2426-2434
The extracellular matrix (ECM) is a major component of the tumor microenvironment, contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In multiple myeloma (MM), interactions between MM cells and the bone ma
Autor:
Arnold Bolomsky, Wolfgang Hübl, Martin Willheim, Adalbert Weißmann, Niklas Zojer, Heinz Ludwig, Antonio Palumbo, Alberto Rocci, Veronique Fritz, Karin Schlangen, Ercan Müldür, Daniel Heintel, Stefano Spada
Publikováno v:
American Journal of Hematology. 92:269-278
Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role for IMiD target genes (e.g. CRBN). Moreover, indirect acti
Autor:
Alberto Rocci, Hector Cordero, Don M. Benson, John C. Byrd, Alessandro Canella, Flavia Pichiorri, Erinn M. Hade, Kitty Agarwal, Michael A. Freitas, Craig C. Hofmeister, Owen E. Branson, Antonio Palumbo, Mitch A. Phelps, Sean W. Harshman, Michael E. Paulaitis, Paul D. Ciarlariello, Ashley E. Rosko, Jason A. Dubovsky
Publikováno v:
Journal of Proteomics. 136:89-98
Multiple myeloma (MM) is a hematological malignancy of clonal plasma cells in the bone marrow (BM). The microenvironment plays a key role in MM cell survival and drug resistance through release of soluble factors, expression of adhesion molecules and
Autor:
Heinz Ludwig, Alberto Rocci, Sabine Pfeifer, Arnold Bolomsky, Ulrich Jäger, S. Caltagirone, Heinz Gisslinger, Martin Schreder, Niklas Zojer, Antonio Palumbo, Daniel Heintel
Publikováno v:
British Journal of Haematology. 161:695-700
Summary Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide. Here, we studied CRBN expression by real time polymerase chain reaction in 49 bo
Autor:
Martin Wilheim, Stefano Spada, Alberto Rocci, Karin Schlangen, Adalbert Weißmann, Antonio Palumbo, Niklas Zojer, Ercan Müldür, Daniel Heintel, Heinz Ludwig, Veronique Fritz, Arnold Bolomsky, Wolfgang Hübl
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:e91
Autor:
Luca Agnelli, Gabriella Sammarelli, Francesco Piazza, Marina Bolzoni, Antonino Neri, Antonio Palumbo, Alberto Rocci, Nicola Giuliani, Paola Storti, Gianpietro Semenzato, Benedetta Dalla Palma, Katia Todoerti
Publikováno v:
American Journal of Hematology. 86:E64-E66
Homeobox (HOX) gene transcription factors are frequently deregulated in hematologic malignancies and involved in leukemogenic transformation [1]. Moreover, their overexpression has been associated with tumoral-induced neoangiogenesis in solid cancer
Autor:
Gambella, Manuela, Rocci, Alberto, Passera, Roberto, Gay, Francesca, Omedè, Paola, Crippa, Claudia, Corradini, Paolo, Romano, Alessandra, Rossi, Davide, Ladetto, Marco, Boccadoro, Mario, Palumbo, Antonio
Multiple myeloma (MM) is a hematologic tumor characterized by accumulation of monoclonal plasma cells (PCs) in the bone marrow (BM) producing antigen-specific immunoglobulins. The transcription factor X box binding protein 1 (XBP1), the interferon re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2eaaeadb291556e8134bb63163e7d00
https://hdl.handle.net/20.500.11769/542317
https://hdl.handle.net/20.500.11769/542317
Autor:
Sean W. Harshman, Michael E. Paulaitis, Tiffany Talabere, Yvonne A. Efebera, Flavia Pichiorri, Kitty Agarwal, Paul D. Ciarlariello, Alessandro Canella, Don M. Benson, Michael A. Freitas, Craig C. Hofmeister, Alberto Rocci, Emily Smith
Publikováno v:
PROTEOMICS.
Multiple myeloma (MM) is a hematological malignancy caused by a microenviromentally aided persistence of plasma cells in the bone marrow. The role that extracellular vesicles, microvesicles and exosomes, released by MM cells have in cell-to-cell comm